CDK4/6 Inhibitor Abemaciclib Arrests and Reverses Kidney Cyst Progression in Preclinical Models of Autosomal Dominant Polycystic Kidney Disease

The authors investigate whether the CDK4/6 inhibitor abemaciclib can effectively arrest and reverse kidney cyst progression in preclinical models of autosomal dominant polycystic kidney disease (ADPKD), a condition currently managed only modestly by tolvaptan. Their findings demonstrate that abemaciclib significantly suppresses cyst growth and improves kidney function by restoring ciliary polycystin levels, showing greater efficacy and tolerability compared to existing treatments.